Patents Examined by Amanda L Aguirre
  • Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
    Patent number: 9974772
    Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: May 22, 2018
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • Materials for electronic devices
    Patent number: 9978949
    Abstract: The application relates to a compound of a formula (I) which is suitable for use as functional material in electronic devices.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: May 22, 2018
    Assignee: Merck Patent GmbH
    Inventors: Teresa Mujica-Fernaud, Elvira Montenegro, Frank Voges, Jonas Valentin Kroeber, Philipp Stoessel
  • N-substituted imidazole carboxylic ester chiral compound containing an ether side chain, its preparation and application
    Patent number: 9969695
    Abstract: The present invention relates to an N-substituted imidazole carboxylic ester chiral compound containing an ether side chain and to its preparation and application. The structure of this compound is represented by Formula (I). This compound can induce a rapid and reversible general anesthesia effect. Animal experiments show that this compound has rapid and short-acting pharmacological characteristics, so that it can be used as a rapid and short-acting general anesthesia medicine. Compared with etomidate, this compound can reduce the inhibition on the synthesis of adrenal cortical hormone, with an advantage of rapid and full recovery of the post-operative patient. The only chiral carbon in the compound structure belongs to the R form.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: May 15, 2018
    Assignee: WEST CHINA HOSPITAL, SICHUAN UNIVERSITY
    Inventors: Wensheng Zhang, Jun Yang, Jin Liu, Lei Tang, Bowen Ke
  • Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
    Patent number: 9956205
    Abstract: Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: May 1, 2018
    Assignee: Ardea Biosciences, Inc.
    Inventors: Laszlo R. Treiber, Irina Zamansky, Jean-Luc Girardet
  • Formulation of syk inhibitors
    Patent number: 9949932
    Abstract: Disclosed are pharmaceutical compositions comprising a compound having the formula: or a pharmaceutically acceptable salt thereof, or a hydrate of thereof, and at least one pharmaceutically acceptable polymer. The pharmaceutically acceptable salt of the compound of Formula I, or a hydrate thereof, can be a mesylate salt, including, for example, a mono-mesylate or a bis-mesylate salt, or a hydrate thereof. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: April 24, 2018
    Assignee: Gilead Connecticut, Inc.
    Inventors: Melissa Jean Casteel, Bei Li, Rowchanak Pakdaman, Diana Sperger, Dimitrios Stefanidis
  • Substituted heteroaryl compounds and methods of use
    Patent number: 9938257
    Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: April 10, 2018
    Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Ning Xi, Minxiong Li, Xiaobo Li, Wuhong Chen, Tao Zhang, Haiyang Hu, Weilong Dai, Yanjun Wu
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 9932347
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: April 3, 2018
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Pyrazole compounds and their use as T-type calcium channel blockers
    Patent number: 9932314
    Abstract: The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: April 3, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Romain Siegrist, Bibia Heidmann, Simon Stamm, John Gatfield, Olivier Bezencon
  • Helquats with heteroaromatic substituents, preparation thereof, and use thereof as G-quadruplex stabilizers
    Patent number: 9932339
    Abstract: Helquat derivatives of general formula I, in which substituents R1 and R2 are independently selected from a group comprising H and C1 to C4 alkyl, up to three of S1,2, S1?,2?, S3,4 and S3?,4? are present, each of S1,2, S1?,2?, S3,4 and S3?,4? independently represents a linker consisting of a bivalent hydrocarbon chain having 3-6 carbon atoms, preferably hydrocarbon chain having 4 carbon atoms, and one to four atoms selected from the carbon atoms with the descriptor 2, 4, 2?, and 4? are substituted with a substituent R3 of general formula II, wherein R4 is substituted or unsubstituted heteroaryl, T1 and T2 are independent linkers that bridge atoms N5 with C8 and N5? with C8?, wherein T1 and T2 independently represent a bivalent hydrocarbon chain having 2-5 carbon atoms, preferably 2 or 3 carbon atoms; and anions (X1)? and (X2)? independently represent anions of pharmaceutically acceptable salts.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: April 3, 2018
    Assignees: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I., VYSOKA SKOLA CHEMICKO-TECHNOLOGICKA V PRAZE
    Inventors: Filip Teply, Miroslav Hajek, Erika Kuzmova, Jaroslav Kozak, Veronika Komarkova, Pavla Hubalkova, Paul Eduardo Reyes-Gutierrez, Michael Jirasek, Manoj R. Sonawane, Vishwas D. Joshi, Lukas Severa, Jana Novotna
  • Process for the asymmetric oxidation of organic compounds with peroxides in the presence of a chiral acid catalyst
    Patent number: 9932305
    Abstract: The present invention relates to a process for the asymmetric oxidation of nucleophilic organic compounds, particularly metal-free, with peroxide compounds in the presence of a chiral Brønsted acid catalyst. In one detail, the present invention relates to a process for enantioselective sulfoxidation of thiocompounds with peroxide compounds in the presence of a chiral imidodiphosphate catalyst. In another detail, the present invention relates to a process for enantioselective sulfoxidation of thiocompounds with peroxide compounds in the presence of a chiral phosphoric acid catalyst.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: April 3, 2018
    Assignee: STUDIENGESELLSCHAFT KOHLE MBH
    Inventors: Benjamin List, Ilija Coric, Saihu Liao
  • Benzimidazole derivatives as RLK and ITK inhibitors
    Patent number: 9932329
    Abstract: The present disclosure is directed to certain inhibitors of RLK and ITK of formula (I), pharmaceutical compositions comprising such compounds, and method of treating diseases mediated by inhibition of RLK and ITK.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: April 3, 2018
    Assignee: PRINCIPIA BIOPHARMA, INC.
    Inventors: Timothy Owens, Ronald J. Hill
  • Imidazolium salts having liquid crystal characteristics, useful as electrolytes
    Patent number: 9932316
    Abstract: Novel imidazolium salts of formula (I) are described in which R is a C1-C14 alkyl group, optionally substituted by one or more fluorine atoms, or a C2-C18 alkoxyalkyl group, R? is an alkyl group containing at least 8 carbon atoms, at least 6 of which are partially or entirely fluorinated, R? is hydrogen or C1-C3 alkyl, Z is an organic or inorganic anion, and Q is further defined. The compounds of formula (I) are liquid crystals over a wide temperature range, and are characterized by high conductivity, hydrophobicity and stability. These properties made them ideally suitable for use in devices based on electrochemical reactions, such as solar cells, fuel cells, electrochemical sensors, lithium batteries and capacitors, etc.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: April 3, 2018
    Assignee: DAUNIA SOLAR CELL S.R.L.
    Inventors: Giuseppe Resnati, Pierangelo Metrangolo, Antonio Abate, Francesco Matteucci
  • Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
    Patent number: 9932353
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: April 3, 2018
    Assignee: ViiV HEALTHCARE UK (NO. 5) LIMITED
    Inventors: B. Narasimhulu Naidu, Manoj Patel
  • N-hydroxymethanesulfonamide nitroxyl donors
    Patent number: 9932303
    Abstract: The disclosed subject matter provides N-hydroxymethanesulfonamide compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: April 3, 2018
    Assignee: Cardioxyl Pharmaceuticals, Inc.
    Inventors: Vincent Jacob Kalish, Frederick Arthur Brookfield, Stephen Martin Courtney, Lisa Marie Frost
  • Process for preparing 5-fluoro-1-methyl-3-difluoromethyl-1H-pyrazole-4-carbaldehyde
    Patent number: 9932312
    Abstract: The present invention relates to a novel process for preparing 5-fluoro-1-methyl-3-difluoromethyl-1H-pyrazole-4-carbaldehyde, a useful intermediate in the manufacture of fungicides.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: April 3, 2018
    Assignee: BAYER CROPSCIENCE AG
    Inventors: Norbert Lui, Sergii Pazenok
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 9925169
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: March 27, 2018
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • Fluorine-containing silane compound
    Patent number: 9926339
    Abstract: A novel fluorine-containing silane compound is provided. The fluorine-containing silane compound is capable of providing excellent water repellency and oil repellency, and is useful as a fluorine-containing silane coupling agent with applicability to a wide variety of applications, even if it has a chemical structure, which is free of a perfluoroalkyl group of 8 or more of carbon atoms; and has no risk of formation of PFOS or PFOA causing bioaccumulation potential and environment adaptability problems. A fluorine-containing silane compound containing at least one of each of a nitrogen-containing perfluoroalkyl group and an alkoxysilyl group in the molecule is selected.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: March 27, 2018
    Assignees: MITSUBISHI MATERIALS CORPORATION, MITSUBISHI MATERIALS ELECTRONIC CHEMICALS CO., LTD
    Inventors: Masato Fujita, Daisuke Takano, Masakazu Uotani, Takeshi Kamiya, Tsunetoshi Honda
  • Inhibitors of bruton's tyrosine kinase
    Patent number: 9926299
    Abstract: The invention provides novel poly-substituted 5-membered heterocyclic compounds represented by Formula (IV), or a pharmaceutically acceptable salt, solvate, metabolite, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as selective irreversible bruton's tyrosine kinase (Btk) inhibitors and are further useful to treat inflammatory, auto immune diseases associated with aberrant B-cell proliferation such as RA (rheumatoid arthritis) and cancers. This invention also provides the preparation of a medicament using of Formula (IV), and methods of preventing or treating diseases associated with excessive Btk activity in mammals, especially humans.
    Type: Grant
    Filed: November 29, 2013
    Date of Patent: March 27, 2018
    Assignee: Centaurus BioPharma Co., Ltd.
    Inventors: Yongxin Han, Rong Yu, Zanping Wang, Zhi Liang, Quan Hu, Li Zhu, Yuandong Hu, Yinghui Sun, Na Zhao, Yong Peng, Xiaofeng Zhai, Hong Luo, Dengming Xiao
  • Hydantoins that modulate BACE-mediated APP processing
    Patent number: 9926280
    Abstract: In certain embodiments hydantoin compounds are provided herein that are effective to inhibit BACE activity against APP. Without being bound to a particular theory, it is believed the activity of the hydantoins identified herein appears to be associated with binding to BACE and/or to APP particularly when these moieties form a BACE/APP complex. Accordingly, it is believed the compounds described herein represent a new class of compounds designated herein as APP-Binding-BACE Inhibitors (ABBIs) and provide a new mechanism to modulate APP processing. The hydantoins described herein appear to show improved brain permeability and functional BACE inhibition.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: March 27, 2018
    Assignee: Buck Institute for Research on Aging
    Inventors: Varghese John, Dale E. Bredesen
  • Ionic tags for synthesis of oligoribonucleotides
    Patent number: 9920084
    Abstract: The invention relates to the chemical synthesis of oligonucleotides, e.g., oligoribonucleotides. In another aspect, the invention relates to compounds of formula (II) processes for making these compounds, and the use thereof in the chemical synthesis of oligonucleotides, e.g., oligoribonucleotides. The invention also relates to methods of synthesis of oligomers, including but not limited to oligopeptides, oligosaccharides and oligonucleotides, particularly oligoribonucleotides and also oligodeoxyribonucleotides, in solution systems, and ionic tag linkers for use in methods provided herein.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: March 20, 2018
    Assignees: The Royal Institution for the Advancement of Learning/McGill University, Hong Kong Polytechnic University
    Inventors: Masad J. Damha, Matthew Hassler, Tak-Hang Chan, Mallikarjuna Reddy Nandyala, Robert Alexander Donga